IP Library Patent Application 19176652
Patent Application
App. No. 19/176,652

NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
19/176,652
Abstract

Provided herein is a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R 1a , R 1b , R 2a , R 2b , R 3 , R 4a , R 4b , R 5 , R 6a , R 16b , R 7a , R 7a , R 11a , R 11b , R 12a , R 12b , R 16a , R 16b , R 19 , R 11a , R 22 , R X , R Y and n are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.

Claims (52)

1 - 104 . (canceled)

105 . A compound of Formula (I-e6):

wherein:

each of R 2a , R 2b , R 15a , and R 15b is hydrogen;

R 3 is unsubstituted C 1-3 alkyl, —CH 2 OCH 3 , or —CH 2 OCH 2 CH 3 ;

R 19 is hydrogen, methyl, or ethyl;

R X is —OH;

R Y is methyl; and

R 22 is —CN.

106 . The compound of claim 105 , wherein R 3 is methyl.

107 . The compound of claim 105 , wherein R 3 is ethyl.

108 . The compound of claim 105 , wherein R 3 is propyl.

109 . The compound of claim 105 , wherein R 3 is —CH 2 OCH 3 .

110 . The compound of claim 105 , wherein R 3 is —CH 2 OC 2 H 5 .

111 . The compound of claim 105 , wherein R 19 is hydrogen.

112 . The compound of claim 105 , wherein R 19 is methyl.

113 . A compound selected from:

Com-

pound

No.

Structure

2

3

7

11

15

24

26

29

42

44

114 . The compound of claim 113 , wherein the compound has the structural formula

115 . The compound of claim 113 , wherein the compound has the structural formula

116 . The compound of claim 113 , wherein the compound has the structural formula

117 . The compound of claim 113 , wherein the compound has the structural formula

118 . The compound of claim 113 , wherein the compound has the structural formula

119 . The compound of claim 113 , wherein the compound has the structural formula

120 . The compound of claim 113 , wherein the compound has the structural formula

121 . The compound of claim 113 , wherein the compound has the structural formula

122 . The compound of claim 113 , wherein the compound has the structural formula

123 . The compound of claim 113 , wherein the compound has the structural formula

124 . A pharmaceutical composition comprising a compound according to claim 105 , and a pharmaceutically acceptable excipient.

125 . A pharmaceutical composition comprising a compound according to claim 114 , and a pharmaceutically acceptable excipient.

126 . A pharmaceutical composition comprising a compound according to claim 115 , and a pharmaceutically acceptable excipient.

127 . A pharmaceutical composition comprising a compound according to claim 116 , and a pharmaceutically acceptable excipient.

128 . A pharmaceutical composition comprising a compound according to claim 117 , and a pharmaceutically acceptable excipient.

129 . A pharmaceutical composition comprising a compound according to claim 118 , and a pharmaceutically acceptable excipient.

130 . A pharmaceutical composition comprising a compound according to claim 119 , and a pharmaceutically acceptable excipient.

131 . A pharmaceutical composition comprising a compound according to claim 120 , and a pharmaceutically acceptable excipient.

132 . A pharmaceutical composition comprising a compound according to claim 121 , and a pharmaceutically acceptable excipient.

133 . A pharmaceutical composition comprising a compound according to claim 122 , and a pharmaceutically acceptable excipient.

134 . A pharmaceutical composition comprising a compound according to claim 123 , and a pharmaceutically acceptable excipient.

Assignments (2)
CHANGE OF NAME Recorded Apr 23, 2026
From: SAGE THERAPEUTICS, INC.
To: SAGE THERAPEUTICS, LLC
Reel/Frame 075472/0569 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2025
From: SALITURO, FRANCESCO G.; BLANCO-PILLADO, MARIA JESUS; MORNINGSTAR, MARSHALL LEE
To: SAGE THERAPEUTICS, INC.
Reel/Frame 071282/0222 →